Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
11%
Ph early_phase_1
4
44%
Ph phase_1
4
44%

Phase Distribution

8

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
4(44.4%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 14 (44.4%)
Phase 14 (44.4%)
Phase 21 (11.1%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions

NCT03898193
completedearly_phase_1

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

NCT01659918
completedearly_phase_1

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions

NCT01659892
completedearly_phase_1

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

NCT01659931
completedearly_phase_1

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions

NCT01659905
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03898193Phase 1

Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions

Completed
NCT01659918Early Phase 1

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

Completed
NCT01659892Early Phase 1

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions

Completed
NCT01659931Early Phase 1

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

Completed
NCT01659905Early Phase 1

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions

Completed
NCT00273013Phase 1

Study With GW274150 In Patients With Mild Asthma

Completed
NCT02480049Phase 1

A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)

Completed
NCT02479854Phase 1

Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)

Completed
NCT01424124Phase 2

Safety and Efficacy of YHD001 in Asthma

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9